While the dollar amount is small relative to market cap, the participation of the CEO in open-market selling is a notable negative signal. Traders should monitor for further selling and assess whether this reflects broader concerns about valuation or fundamentals ahead of earnings or other catalysts.
LH drugs
LH drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 24 $286.41entry
- T+1 · 9mo ago −1.51%α −2.35% · $282.07
- T+5 · 9mo ago −1.19%α −0.16% · $282.99
- T+20 · 8mo ago −7.08%α −2.10% · $266.12
- T+60 · 6mo ago −11.42%α −18.17% · $253.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
LH CEO Adam Schechter sold $2.44M in shares, followed by EVP Sandra van der Vaart selling $156K, both via open-market transactions within the past week. These sales represent modest insider selling from two C-suite executives.
Key Financial Metrics
Key Facts
- CEO Adam Schechter sold 8,705 shares at $279.96, totaling $2.44 million in open-market transaction.
- EVP Sandra van der Vaart sold 547.54 shares at $284.91, totaling $156,000 in open-market sale.
- Both transactions occurred within a 7-day window, indicating a coordinated cluster of insider selling.
- Total value of the cluster: $2.6 million, representing 0.011% of LH's $23.1B market cap.
Financial Impact
$2.6 million in total open-market insider sales
Risk Factors
- Insider selling by CEO may signal lack of confidence in near-term prospects or overvaluation.
- Potential for negative market perception despite relatively small transaction size.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (2 trades, 7d window) | cluster-LH-1772719080988 |
Track record
29 reports on LH
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +17.60% at T+60 after the Apr 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $372.32 Now $372.46 +0.04% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $372.23 Now $372.46 +0.06% settles Nov 18
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $363.30 to $372.32 Now $372.46 +2.52% ▲ +2.48% −0.81% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 4, 202612d ago 8-K Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $353.92 to $370.88 Now $372.46 +5.24% ▲ +4.79% +5.38% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $361.39 to $366.57 Now $372.46 +3.06% ▲ +1.43% +4.14% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $360.25 to $367.79 Now $372.46 +3.39% ▲ +2.09% +2.81% vs SPY
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $329.90 to $361.39 Now $372.46 +12.90% ▲ +9.55% +10.81% vs SPY
- Oct 21, 202626d ago 8-K Neutral 2/10 Entry $323.75 to $331.17 Now $372.46 +15.05% ▲ +2.29% +2.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers